Search

Your search keyword '"Horiguchi, Shigeru"' showing total 329 results
Start Over Author "Horiguchi, Shigeru" Language english
329 results on '"Horiguchi, Shigeru"'

1. Effectiveness of data-augmentation on deep learning in evaluating rapid on-site cytopathology at endoscopic ultrasound-guided fine needle aspiration

Author

Fujii, Yuki, Uchida, Daisuke, Sato, Ryosuke, Obata, Taisuke, Akihiro, Matsumi, Miyamoto, Kazuya, Morimoto, Kosaku, Terasawa, Hiroyuki, Yamazaki, Tatsuhiro, Matsumoto, Kazuyuki, Horiguchi, Shigeru, Tsutsumi, Koichiro, Kato, Hironari, Inoue, Hirofumi, Cho, Ten, Tanimoto, Takayoshi, Ohto, Akimitsu, Kawahara, Yoshiro, and Otsuka, Motoyuki

Published
2024
Full Text
View/download PDF

2. Virtual indigo carmine chromoendoscopy images: a novel modality for peroral cholangioscopy using artificial intelligence technology (with video)

Author

Sato, Ryosuke, Matsumoto, Kazuyuki, Kinugasa, Hideaki, Tomiya, Masahiro, Tanimoto, Takayoshi, Ohto, Akimitsu, Harada, Kei, Hattori, Nao, Obata, Taisuke, Matsumi, Akihiro, Miyamoto, Kazuya, Morimoto, Kosaku, Terasawa, Hiroyuki, Fujii, Yuki, Uchida, Daisuke, Tsutsumi, Koichiro, Horiguchi, Shigeru, Kato, Hironari, Kawahara, Yoshiro, and Otsuka, Motoyuki

Published
2024
Full Text
View/download PDF

7. Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding

Author

Terasawa, Hiroyuki, Matsumoto, Kazuyuki, Tanaka, Takehiro, Tomoda, Takeshi, Ogawa, Taiji, Ishihara, Yuki, Kikuchi, Tatsuya, Obata, Taisuke, Oda, Takashi, Matsumi, Akihiro, Miyamoto, Kazuya, Morimoto, Kosaku, Fujii, Yuki, Yamazaki, Tatsuhiro, Uchida, Daisuke, Horiguchi, Shigeru, Tsutsumi, Koichiro, Kato, Hironari, and Otsuka, Motoyuki

Published
2023
Full Text
View/download PDF

12. Clinical characteristics of immunoglobulin IgG4-related sclerosing cholangitis: Comparison of cases with and without autoimmune pancreatitis in a large cohort

Author

Furumatsu, Keisuke, Sawai, Shigeaki, Goto, Takuma, Okumura, Toshikatsu, Suzuki, Daisuke, Otsuka, Masayuki, Kobori, Ikuhiro, Tamano, Masaya, Koizumi, Mitsuhito, Hiasa, Yoichi, Kawabe, Naoto, Hirooka, Yoshiki, Yamamoto, Satoshi, Asano, Yukio, Inui, Kazuo, Horiguchi, Akihiko, Watanabe, Hiroyuki, Toya, Daishu, Hatayama, Katsuko, Ueki, Toshiharu, Kinoshita, Norikatsu, Sugimoto, Mitsuru, Ohira, Hiromasa, Mukai, Tsuyoshi, Tomita, Eiichi, Iwata, Keisuke, Shimizu, Shogo, Suetsugu, Jun, Shimizu, Masahito, Tsuji, Keiji, Ishida, Ryoko, Ito, Masanori, Furukawa, Ryutaro, Sakamoto, Naoya, Araki, Masahiro, Tanno, Satoshi, Sakamoto, Yasunari, Ito, Tetsuhide, Takai, Satoshi, Ikeya, Shinichi, Yamada, Takanori, Kudara, Norihiko, Shimizu, Akinori, Hanada, Keiji, Ichiki, Yasunori, Kitada, Hideki, Hifumi, Michio, Kimura, Hiroyuki, Kurosaki, Masayuki, Izumi, Namiki, Sumi, Hajime, Haruta, Jun-ichi, Hayashi, Katsumi, Harada, Ryo, Inoue, Masafumi, Nakamura, Shinichiro, Ito, Tetsuya, Tomishima, Ko, Isayama, Hiroyuki, Oura, Kyoko, Masaki, Tsutomu, Shimokawahara, Naoto, Tanoue, Shirou, Maemura, Kousei, Ido, Akio, Mizushima, Ichiro, Kawano, Mitsuhiro, Yoshida, Katsunori, Naganuma, Makoto, Murata, Miki, Nishio, Akiyoshi, Fujita, Yuji, Teratani, Takuma, Matsubara, Shohei, Tamai, Hironao, Yoshida, Yuu, Azemoto, Ryousaku, Kamata, Ken, Watanabe, Tomohiro, Kurosu, Takahiro, Koizumi, Wasaburou, Fujita, Jun, Seki, Hideyuki, Ueda, Yasuhiro, Fukumoto, Takumi, Kousaki, Takuhiro, Uchida, Kazushige, Ochiai, Toshimasa, Kawasaki, Takeshi, Tanaka, Motohiko, Ishida, Etsuji, Notohara, Kenji, Mori, Hideaki, Mori, Toshiyuki, Kawabata, Hideaki, Miyata, Masatoshi, Sakagami, Junichi, Itoh, Yoshito, Shiokawa, Masahiro, Seno, Hiroshi, Watanabe, Noriko, Naitoh, Itaru, Kataoka, Hiromi, Aoki, Toshinori, Fujishiro, Mitsuhiro, Niihara, Toru, Nishimata, Hiroto, Mitoro, Akira, Yoshiji, Hitoshi, Yoshida, Motoyuki, Ikeda, Masafumi, Tomita, Kengo, Hokari, Ryota, Hayasaka, Kenji, Amano, Yuji, Shioji, Kazuhiko, Hayashi, Kazunao, Terai, Shuji, Nakajima, Michiko, Yamahana, Junya, Matsumoto, Ryusuke, Kikuchi, Hideaki, Kanamori, Akira, Kiriyama, Seiki, Iwatsu, Shinichi, Kato, Yuji, Horiguchi, Shigeru, Yagi, Takahito, Okada, Hiroyuki, Ohkawa, Kazuyoshi, Hirao, Motohiro, Hiramatsu, Naoki, Oza, Noriko, Imamura, Haruo, Baba, Takeshi, Nakano, Shigeru, Shinobi, Tetsuya, Ryozawa, Shomei, Motoya, Masayo, Nakase, Hiroshi, Kinoshita, Noboru, Ito, Kei, Miyake, Tatsuya, Kohge, Naruaki, Tobita, Hiroshi, Joshita, Satoru, Umemura, Takeji, Kawaguchi, Shinya, Ohno, Kazuya, Sonobe, Koichi, Satoh, Akihiko, Shimosegawa, Tooru, Miura, Fumihiko, Yagi, Minami, Sano, Keiji, Tanaka, Atsushi, Kin, Toshifumi, Katanuma, Akio, Koike, Kazuhiko, Miura, Shin, Masamune, Atsushi, Kawashima, Youhei, Kagawa, Tatehiro, Azuma, Seishin, Watanabe, Mamoru, Honjyo, Mitsuyoshi, Itoi, Takao, Honda, Akira, Kobayashi, Katsumasa, Asano, Toru, Kamisawa, Terumi, Mizuno, Suguru, Nishino, Takayoshi, Taniguchi, Hideaki, Tajiri, Kazuto, Yasuda, Ichiro, Tanaka, Yoshiya, Oe, Shinji, Harada, Masaru, Kurata, Masanao, Fukasawa, Mituharu, Enomoto, Nobuyuki, Kawaji, Yuki, Kitano, Masayuki, Nishise, Yuko, Hirakawa, Hidetoshi, Ishizawa, Tetsuya, Ueno, Yoshiyuki, Kaino, Miyuki, Fujimoto, Yuko, Sakaida, Isao, Kubota, Kensuke, Nakazawa, Takahiro, Takikawa, Hajime, Unno, Michiaki, Kawa, Shigeyuki, Nakamura, Seiji, and Okazaki, Kazuichi

Published
2021
Full Text
View/download PDF

23. A Comparison of the Efficacy of Plastic Stent Placement Above and Across the Sphincter of Oddi for Benign Biliary Hilar Stricture

Author

Himei, Hitomi, Kato, Hironari, Saragai, Yosuke, Fujii, Yuki, Yamazaki, Tatsuhiro, Uchida, Daisuke, Matsumoto, Kazuyuki, Horiguchi, Shigeru, Tsutsumi, Koichiro, and Okada, Hiroyuki

Subjects
plastic stent, inside stent, benign biliary stricture
Abstract

We investigated the efficacy and safety of endoscopic plastic stent (PS) placement for hilar benign biliary strictures (BBSs) and compared cases with PS placement above (inside stent, IS) and across (usual stent, US) the sphincter of Oddi. Patients who underwent initial endoscopic PS placement for hilar BBSs between August 2012 and December 2021 were retrospectively analyzed. Hilar BBSs in 88 patients were investigated. Clinical success was achieved in 81 of these cases (92.0%), including 38 patients in the IS group and 43 patients in the US group. Unexpected stent exchange (uSE) before the first scheduled PS exchange occurred in 18 cases (22.2%). The median time from first stent placement to uSE was 35 days. There was no significant difference in the rate and median time to uSE between the two groups. The rates of adverse events such as pancreatitis or cholangitis in the two groups did not significantly differ. However, the rate of difficult stent removal in the IS group (15.8%) was significantly higher than that in the US group (0%) (p=0.0019). US placement is preferable to IS placement for scheduled stent exchange, as it offers the same effectiveness and risk of adverse events with easier stent removal.

Published
2023

26. Association of screening tool scores with overall survival in older patients with unresectable gastrointestinal or biliary pancreatic cancer: A retrospective study

Author

Inoo, Shoko, Kono, Yoshiyasu, Kanzaki, Hiromitsu, Horiguchi, Shigeru, Kato, Hironari, Yamasaki, Yasushi, Hirata, Shoichiro, Kuraoka, Sakiko, Matsueda, Katsunori, Okanoue, Shotaro, Satomi, Takuya, Hamada, Kenta, Iwamuro, Masaya, Kawano, Seiji, Kawahara, Yoshiro, Okada, Hiroyuki, and Otsuka, Motoyuki

Published
2024
Full Text
View/download PDF

27. Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens

Author

Takahashi, Hideaki, Ikeda, Masafumi, Shiba, Satoshi, Imaoka, Hiroshi, Todaka, Akiko, Shioji, Kazuhiko, Yane, Kei, Kojima, Yasushi, Kobayashi, Satoshi, Asagi, Akinori, Ozaka, Masato, Takada, Ryoji, Nagashio, Yoshikuni, Horiguchi, Shigeru, Kasuga, Akiyoshi, Suzuki, Eiichiro, Terashima, Takeshi, Ueno, Makoto, Morizane, Chigusa, and Furuse, Junji

Published
2021
Full Text
View/download PDF

32. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy

Author

Shibuya, Hitoshi, Hijioka, Susumu, Sakamoto, Yasunari, Ito, Tetsuhide, Ueda, Keijiro, Komoto, Izumi, Kobayashi, Noritoshi, Kudo, Atsushi, Yasuda, Hiroaki, Miyake, Hayato, Arita, Junichi, Kiritani, Sho, Ikeda, Masafumi, Imaoka, Hiroshi, Ueno, Makoto, Kobayashi, Satoshi, Furuta, Mitsuhiro, Nagashio, Yoshikuni, Murohisa, Gou, Aoki, Taku, Matsumoto, Shigemi, Motoya, Masayo, Azemoto, Nobuaki, Itakura, Jun, Horiguchi, Shigeru, Yogi, Tatsuji, Kawagoe, Tetsuro, Miyaoka, Youichi, Imamura, Fumito, Senju, Michio, Arioka, Hitoshi, Hara, Kazuo, Imamura, Masayuki, and Okusaka, Takuji

Published
2018
Full Text
View/download PDF

36. Optimal liver drainage rate for survival in patients with unresectable malignant hilar biliary obstruction using 3D-image volume analyzer.

Author

Morimoto, Kosaku, Matsumoto, Kazuyuki, Obata, Taisuke, Oda, Takashi, Miyamoto, Kazuya, Matsumi, Akihiro, Terasawa, Hiroyuki, Fujii, Yuki, Yamazaki, Tatsuhiro, Horiguchi, Shigeru, Tsutsumi, Koichiro, Kato, Hironari, and Otsuka, Motoyuki

Subjects
OVERALL survival, DRAINAGE, SURVIVAL rate, LIVER, CANCER chemotherapy
Abstract

Background: Drainage exceeding 50% of total liver volume is a beneficial prognostic factor in patients with unresectable malignant hilar biliary obstruction (UMHBO). However, it is unclear what threshold percentage of total liver volume drained ('liver drainage rate') significantly improves survival in patients with UMHBO who received systemic chemotherapy. Objectives: We aimed to assess the optimal liver drainage rate that improves survival in patients with UMHBO receiving chemotherapy using a three-dimensional (3D)-image volume analyzer. Design: This study was a single-center retrospective cohort study. Methods: Data from 90 patients with UMHBO who received chemotherapy after endoscopic biliary drainage using metal stents at Okayama University Hospital from January 2003 to December 2020 were reviewed. The liver drainage rate was calculated by dividing the drained liver volume by the total liver volume using a 3D-image volume analyzer. The primary endpoint was overall survival by liver drainage rate. The secondary endpoints were time to recurrent biliary obstruction (TRBO) and prognostic factors. Results: The median total liver volume was 1172 (range: 673–2032) mL, and the median liver drainage rate was 83% (range: 50–100). Overall survival was 376 (95% CI: 271–450) days, and patients with >80% drainage (n = 67) had significantly longer survival than those with <80% drainage (n = 23) (450 days versus 224 days, p = 0.0033, log-rank test). TRBO was 201 (95% CI: 155–327) days and did not differ significantly by liver drainage rate. Multivariate Cox proportional hazards regression analysis revealed >80% liver drainage [hazard ratio (HR): 0.35, 95% CI: 0.20–0.62, p = 0.0003] and hilar cholangiocarcinoma (HR: 0.30, 95% CI: 0.17–0.50, p < 0.0001) as significant prognostic factors. Conclusion: In patients with UMHBO scheduled for chemotherapy, >80% drainage is associated with improved survival. Further prospective multicenter studies are needed to verify the results of this study. Trail registration: Okayama University Hospital, IRB number: 2108-011. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Risk Factors for Ceftriaxone-Associated Pseudolithiasis in Adults.

Author

Matsumi, Akihiro, Tomoda, Takeshi, Terasawa, Hiroyuki, Fujii, Yuki, Yamazaki, Tatsuhiro, Uchida, Daisuke, Matsumoto, Kazuyuki, Horiguchi, Shigeru, Tsutsumi, Koichiro, and Kato, Hironari

Subjects
ADULTS, GLOMERULAR filtration rate, CHRONIC kidney failure, BILIOUS diseases & biliousness, LIVER enzymes
Abstract

Introduction: Ceftriaxone (CTRX) is known to occasionally cause pseudolithiasis. This condition is often observed in children; however, few studies have reported the incidence and risk factors for CTRX-associated pseudolithiasis. Methods: In this single-center retrospective study, we investigated the incidence of and risk factors for CTRX-associated pseudolithiasis in adults. All patients underwent computed tomography to confirm pseudolithiasis before and after CTRX administration. Results: The study included 523 patients. Pseudolithiasis was detected in 89 patients (17%). Data analysis showed that abdominal area-related biliary diseases at the site of infection (odds ratio [OR] 0.19, 95% confidence interval [CI] 0.064–0.53, p = 0.0017), CTRX administration for >3 days (OR 5.0, 95% CI: 2.5–9.9, p < 0.0001), CTRX dose of 2 mg (OR 5.2, 95% CI: 2.8–9.6, p < 0.0001), fasting period >2 days (OR 3.2, 95% CI: 1.6–6.4, p = 0.0010), and estimated glomerular filtration rate <30 mL/min/1.73 m2 (OR 3.4, 95% CI: 1.6–7.5, p = 0.0022) were independent factors for pseudolithiasis. Conclusions: CTRX-associated pseudolithiasis may occur in adults and should be considered in the differential diagnosis in patients who develop abdominal pain or liver enzyme elevation after CTRX administration, particularly in patients with chronic kidney disease, in those who are fasting, in and those who receive high-dose CTRX therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf‐3 expressing adenoviral vector for hepatocellular carcinoma

Author

Sawahara, Hiroaki, Shiraha, Hidenori, Uchida, Daisuke, Kato, Hironari, Kato, Ryo, Oyama, Atsushi, Nagahara, Teruya, Iwamuro, Masaya, Horiguchi, Shigeru, Tsutsumi, Koichiro, Mandai, Mari, Mimura, Tetsushige, Wada, Nozomu, Takeuchi, Yasuto, Kuwaki, Kenji, Onishi, Hideki, Nakamura, Shinichiro, Watanabe, Masami, Sakaguchi, Masakiyo, Takaki, Akinobu, Nouso, Kazuhiro, Yagi, Takahito, Nasu, Yasutomo, Kumon, Hiromi, and Okada, Hiroyuki

Published
2017
Full Text
View/download PDF

44. Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma

Author

Takahashi, Hideaki, Ikeda, Masafumi, Shiba, Satoshi, Imaoka, Hiroshi, Todaka, Akiko, Shioji, Kazuhiko, Yane, Kei, Kojima, Yasushi, Kobayashi, Satoshi, Asagi, Akinori, Ozaka, Masato, Takada, Ryoji, Nagashio, Yoshikuni, Horiguchi, Shigeru, Kasuga, Akiyoshi, Suzuki, Eiichiro, Terashima, Takeshi, Ueno, Makoto, Morizane, Chigusa, and Furuse, Junji

Subjects
Aged, 80 and over, Adult, Male, Time Factors, Adolescent, Carcinoma, Acinar Cell, pancreatic neoplasms, Platinum Compounds, Original Articles, Middle Aged, chemotherapy, Irinotecan, Progression-Free Survival, Young Adult, Japan, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Humans, Female, 5-fluorouracil, platinum, Child, acinar cell carcinoma, Aged, Retrospective Studies
Abstract

Objectives The aim of this multicenter retrospective study was to identify the optimal chemotherapeutic regimen for advanced pancreatic acinar cell carcinoma (PACC). Methods Fifty-eight patients with histopathologically confirmed advanced PACC who had received chemotherapy between 1996 and 2013 were enrolled. The clinical characteristics of the patients and the treatment efficacy data were collected from the medical records at 16 Japanese institutions, using standardized data collection instrument. Results The most commonly selected treatment regimens were gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens. The overall response rate in the patients who received first-line chemotherapy were 7% and 38%, respectively, and the median overall survival was 13.2 months. When the data for all the treatment lines were aggregated, the response rates to gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens were 7%, 18%, 40%, and 29%, respectively. The overall survival tended to be better in patients who had received a platinum-containing regimen (hazard ratio, 0.50; 95% confidence interval, 0.23–1.11; P = 0.08) or irinotecan-containing regimen (hazard ratio, 0.42; 95% confidence interval, 0.15–1.19; P = 0.09) at least once in the treatment course as compared with those who had not. Conclusions Our findings suggested that platinum- and irinotecan-containing regimens exhibited some potential efficacy in patients with advanced PACC.

Published
2020

48. Study Protocol for a Trial: A Single-Arm, Open-Labeled Study Evaluating Transcatheter Arterial Embolization Plus Everolimus Combination Therapy for Patients With Liver Metastasis of Gastroenteropancreatic Neuroendocrine Tumors.

Author

Takeuchi, Yasuto, Kato, Hironari, Horiguchi, Shigeru, Oyama, Atsushi, Adachi, Takuya, Wada, Nozomu, Onishi, Hideki, Shiraha, Hidenori, and Takaki, Akinobu

Abstract

Background: The number of patients with non-functional neuroendocrine tumors (NETs) has increased recently, and the rate of liver metastasis of NETs is about 20% in patients at the first diagnosis. Transcatheter arterial embolization (TAE) and everolimus are therapies with reported efficacy, but few reports have described their combined treatment. We therefore aim to evaluate the efficacy and safety of combination therapy with everolimus and TAE in patients with liver metastasis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in a prospective study. Methods: We design a single-arm, open-label, prospective study to evaluate the efficacy and safety of combination therapy with everolimus and TAE in patients with liver metastases of GEP-NETs. The study started in June 2021 at Okayama University Hospital and is expected to enroll 18 patients over a 2-year period. Discussion: This study is a prospective study investigating a new treatment method for a rare disease called GEP-NETs. We may obtain useful information that contributes to the treatment guidelines in this study. However, NET is a rare disease, and although the number of cases is statistically established, it may not be possible to accurately assess causality. TRIAL REGISTRATION NUMBER: jRCT1061210015. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results